

# Academic Cancer Drug Development: Challenges and Successes

## 25<sup>th</sup> September, 2017, Congress Centre Mauno, BioCity, Turku, Finland

### Program

8.45-8.55 **Kalervo Väänänen**, Rector of the University of Turku. *Opening words*

8.55-9.00 **Anna Knittle**, Chair of the Turku Cancer Research Society. *Opening words*

#### **Session 1** **Small molecule development in academic setting (Chair: Anna Knittle)**

9.00-9.40 **Leonardo Scapozza** (University of Geneva, Switzerland). *Allosterism: Targeting the undruggable?*

9.40-10.20 **Olli Pentikäinen** (University of Turku, Finland). *Rational discovery of protein-protein interaction modulators*

#### **Session 2** **Small molecule development in drug development center setting (Chair: Krista Rantanen)**

10.20-11.00 **Justin Bower** (Beatson Institute of Cancer Research, UK). *Building a capability to translate novel oncology biology*

11.00-11.40 **Matthias Versele** (Centre for Drug Design and Discovery, Belgium). *Drug discovery from hit identification to in vivo proof-of-concept, based on innovative academic science*

11.40-12.00 Coffee

#### **Frontiers of Science seminar (Chair: Daniel Abankwa)**

12.00-13.00 **Marc Therrien** (University of Montreal, Canada). *Structural characterization and pharmacological targeting of dimerization-induced RAF activation*

13.00-14.00 Lunch at your own

#### **Session 3** **From basic research to small molecule development (Chair: Jukka Westermarck)**

14.00-14.40 **Goutham Narla** (Case Western University, OH, USA). *Drugging the undruggable: novel insights from Protein Phosphatase 2A*

14.40-15.20 **Thomas Helleday** (Karolinska Institutet, Sweden). *Targeting DNA repair: the rocky road from basic science discovery to clinical practice*

15.20-15.40 Coffee

#### **Session 4** **From basic research to clinical cancer trials (Chair: Jeroen Pouwels)**

15.40-16.20 **Klas Wiman** (Karolinska Institutet, Sweden). *Pharmacological reactivation of mutant p53 - from molecular biology to the clinic*

16.20-17.00 **Tim Holmström** (Orion Pharma, Finland). *ODM-203, a selective dual FGFR/VEGFR inhibitor in patients with advanced solid tumours*

17.00-17.40 **Antti Rannikko** (Helsinki University Hospital, Finland). *Challenges in clinical trials*

Closure of the meeting: **Jeroen Pouwels**

**Organizers:** Turku Cancer Research Society (<http://cancerresearch.utu.fi>), Centre for Biotechnology, University of Turku and Åbo Akademi University (<http://www.btk.fi/home/main/>)

#### **Organizing committee:**

Adj. Professor Jeroen Pouwels (chair) (University of Turku and University of Helsinki), Dr. Krista Rantanen (University of Turku and University of Tampere), Prof. Jukka Westermarck (University of Turku), Adj. Professor Daniel Abankwa (Åbo Akademi University), Dr. Tiina Arsiola (University of Turku)